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Abstract: 
Objectives: To critically review conceptual frameworks for available patient 
reported outcome (PRO) questionnaires in men having radical 
prostatectomy; psychometrically evaluate each questionnaire; identify 
whether each is appropriate for use at the level of the individual patient.  
 
Materials and Methods: We searched PubMed, the Reports and Publications 
database of the University of Oxford Patient Reported Outcomes 
Measurement Group and the website of the International Consortium for 
Health Outcomes Measurement (ICHOM) for psychometric reviews of 
prostate cancer specific PRO questionnaires.  From these we identified 
relevant questionnaires and critically appraised the conceptual content, 
guided by the Wilson and Cleary framework and psychometric properties, 
using well established criteria.  
 
Results: Searches found four reviews and one recommendation paper.  We 
identified seven prostate cancer specific PROs (EPIC-26, EPIC-50, UCLA-
PCI, FACT-P, QLQ-PR25, and PC-QoL and STAR).  Six out of seven 
measures purported to measure health related quality of life, but items 
focused strongly on urinary and sexual symptoms/functioning.  The 
remaining questionnaire (STAR) claimed to assess functional recovery after 
radical prostatectomy.  The psychometric evidence for these questionnaires 
was incomplete and variable in quality; none had evidence that they were 
appropriate for use with individual patients.  
 
Conclusion: Several questionnaires provide the basis of measures of 
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For Peer Review
urinary and/or sexual symptoms/functioning.  Further work should explore 
other aspects of health related quality of life that are important for men 
having radical prostatectomy.  Further psychometric work is also needed to 
determine whether they can be used at the individual level.   
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Abstract  
 
Background: Patient reported outcome measures (PROs) are used to evaluate the outcomes 
that surgeons consider important functional outcomes of radical prostatectomy (e.g. urinary 
incontinence, erectile dysfunction).  Men themselves are also interested in a wider range of 
outcomes including anxiety, social interactions and intimate relations.  It is therefore 
important to be clear about what a questionnaire is supposed to measure and how well it 
does so. 
 
Objectives: To Ccritically review conceptual frameworks for available patient reported 
outcome (PRO) questionnaires in men having radical prostatectomy; psychometrically 
evaluate each questionnaire; identify whether each is appropriate for use at the level of the 
individual patient.  
 
Materials and Methods: We searched PubMed, the Reports and Publications database of 
the University of Oxford Patient Reported Outcomes Measurement Group and the website 
of the International Consortium for Health Outcomes Measurement (ICHOM) for 
psychometric reviews of prostate cancer specific PRO questionnaires.  From these we 
identified relevant questionnaires and critically appraised the conceptual content, guided by 
the Wilson and Cleary framework and psychometric properties, using well established 
criteria. 
 
Results: Searches found four reviews and one recommendation paper.  We identified seven 
prostate cancer specific PROs (EPIC-26, EPIC-50, UCLA-PCI, FACT-P, QLQ-PR25, and PC-QoL 
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and STAR).  Six out of seven measures purported to measure health related quality of life, 
but items focused strongly on urinary and sexual symptoms/functioning.  The remaining 
questionnaire (STAR) claimed to assess functional recovery after radical prostatectomy.  The 
psychometric evidence for these questionnaires was incomplete and variable in quality; 
none had evidence that they were appropriate for use with individual patients. 
 
Conclusions: Several questionnaires provide the basis of measures of urinary and/or sexual 
symptoms/functioning.  Further work should explore other aspects of health related quality 
of life that are important for men having radical prostatectomy.  Further psychometric work 
is also needed to determine whether they can be used at the individual level.   
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INTRODUCTION 
 
Patient reported outcomes (PROs) are increasingly being used to study outcomes in patients 
diagnosed with prostate cancer.  Patients’ reports of symptoms, function and health-related 
quality of life (HRQL) or overall quality of life (QoL) can provide important information about 
the impact that prostate cancer health problems and related treatments have on patients’ 
men’s lives [1, 2].  These terms are often used interchangeably and for the remainder of this 
paper we will use the term HRQL.  Typically, PROs are used to study outcomes at group 
level.  However, in some prostate cancer centres, a formal tool for the collection of PROs 
has been implemented in routine clinical practice to monitor outcomes in individual 
patients after radical surgery [3]. 
 
In the UK, around 10% of men newly diagnosed with prostate cancer have a radical 
prostatectomy [4]. In addition to cancer cure, surgeons consider the absence of side effects, 
such as urinary incontinence and erectile dysfunction, as important indicators of the success 
of the surgery.  Men themselves are interested in a wider range of outcomes [5], including 
anxiety and distress, social interactions and intimate relations [6], feelings of masculinity, 
and self-esteem [7].  It is therefore important that both developers and users of PRO 
questionnaires for men diagnosed with prostate cancer are clear about what the 
questionnaire is supposed to measure, whether the questionnaire actually measures these 
concepts, and how well it does so. 
 
Several reviews have evaluated the scientific or psychometric properties of existing PRO 
questionnaires that are being used for patients diagnosed with prostate cancer [8-10].  In 
general, these reviews have used well-established guidelines and criteria based on classical-
test theory to evaluate the robustness of existing instruments [11-13].  The performance of 
these instruments is often expressed in terms of reliability (the extent to which an 
instrument is free from error), validity (the extent to which it measures what it aims to 
measure), and responsiveness (the ability to detect clinically important changes over time).  
However, none of the existing reviews has included a critical review of the conceptual 
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content of existing instruments nor evaluated the extent to which these instruments are fit 
to monitor outcomes in individual patients. 
 
To evaluate instruments’ fitness to measure outcomes at the individual level, modern 
psychometric approaches are now often used, such as Rasch measurement theory (RMT) 
and item response theory (IRT) [14-16]. Scores derived from these approaches have a 
number of advantages over methods based on classical-test theory: they are truly “interval 
scores”, meaning that there is an equal distance between each of the values on the scale (as 
opposed to ordinal scores where values are in rank order but the distance between any two 
values may not be equal), “invariant” (independent of both the distribution of items and the 
distribution of the sample), and potentially appropriate for use in individual patients. 
 
Inconsistency about how QoL and HRQL are is defined adds to the complexity of evaluating 
PRO questionnaires that claim to measure these constructs.  Although there is no universal 
definition of HRQL, it is generally agreed that it is multi-dimensional and subjective [17-19].  
That is, HRQL focuses on the perceived impact (from the patient’s perspective) of physical, 
mental and social domains of health.  HRQL is therefore not usually concerned with how 
much of a symptom a patient has, but rather to what extent the patient is “bothered by” or 
“concerned about” that symptom.  In addition, Wilson and Cleary [20] have provided a 
conceptual framework that places HRQL in the wider context of health outcomes and 
suggests how HRQL is related to other health outcomes widely used in clinical and health 
services research.  They distinguish five levels of outcome: “biological and physiological 
variables”, “symptom status”, “functional status”, ”general health perceptions”, and 
“overall QoL”. These five outcomes are considered to be separate constructs that are 
causally related (e.g. “symptom status” will affect “functional status” which in turn is likely 
to affect HRQL).  It is important to note that the “overall QoL” construct in the Wilson and 
Cleary framework should reflect individuals’ subjective perception of how happy or satisfied 
they are with their life as a whole.   
 
To address the shortcomings of previous reviews, and to evaluate whether the HRQL 
outcomes that are important to men are being assessed, wWe carried out a review of the 
existing psychometric reviews of prostate cancer-specific instruments developed to collect 
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PROs.  Our aims were to 1) critically review the conceptual content of available PRO 
questionnaires used in men having radical prostatectomy, 2) psychometrically evaluate each 
instrument and 3) determine the extent to which each instrument is appropriate for use in 
individual patients. We used this review-of-reviews to identify the original development 
articles and we applied the Wilson and Cleary framework as the basis for a critical appraisal 
of the instruments’ conceptual content [20].  We also summarised the available 
psychometric evidence for each instrument and aimed to determineassessed the extent to 
which each instrument is appropriate for use in individual patients. 
 
 
METHODS 
 
Search strategy 
We searched the PubMed database from its beginning to June 2015 to identify 
psychometric reviews of prostate cancer-specific PRO questionnaires.  We searched 
PubMed using the following search strategy: (“quality of life” OR “QoL” OR “HRQL” OR 
“symptom” OR “function” OR “disability” OR “patient reported outcome”) AND (“prostate”) 
AND (“instrument” OR “measure ” OR “questionnaire”), limited by “review” and “systematic 
review”. 
 
To identify additional reviews we searched the Reports and Publications database of the 
University of Oxford Patient Reported Outcomes Measurement Group [21].  We also 
searched the website of the International Consortium for Health Outcomes Measurement 
(ICHOM) for reports of recommendations on prostate cancer-specific PROs [21]. 
 
Instrument selection 
From the identified review papers, we compiled a list of instruments recommended by the 
reviewers following psychometric assessment, and located the original development 
articles.  We excluded instruments developed in languages other than English, generic 
cancer-related instruments, instruments that were designed to capture utilities (i.e. 
quantitative measures of individuals’ preferences for specific health states), instruments not 
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developed for use in patients with prostate cancer, and instruments specifically designed to 
be used in men who had prostate cancer treatments other than radical prostatectomy.  
Single question assessments were also excluded. 
 
Data extraction and appraisal 
We identified and evaluated the original development article(s) for each instrument, and 
extracted data for each instrumentfrom each development article, using a standard data 
extraction form derived from Smith et al 2005 [22].  The criteria used for this appraisal are 
described in Table 1 and based on well-established classical psychometric criteria [11, 12, 
23].  We chose these guidelines because they were specifically focused on the criteria for 
the psychometric properties that an instrument must have, rather than the quality of the 
paper reporting the instrument development, which the COSMIN guidelines address [24]. To 
assess content validity we also undertook a conceptual review of each of the identified 
instruments using the five levels of outcome included in the Wilson and Cleary framework 
[20].  We used this framework as a guide to compare the items of each instrument with the 
construct that each instrument claimed to measure.  For example, if an instrument claimed 
to measure HRQL, we expected items to reflect the subjectively perceived impact of 
physical, mental and social domains of health rather than the objective level of physical, 
mental or social health.  That is, an item measuring HRQL would ask about the extent to 
which a man is concerned or bothered by his symptoms rather than the extent to which he 
has symptoms.  Two authors (SCS, EP) reviewed each instrument using the standard 
extraction form.  These two authors completed the review independently and then 
discussed any discrepancies until reaching consensus. 
 
 
RESULTS 
 
The literature search generated 450 review papers.  447 articles were identified via 
PubMed, while three articles were identified from the remaining sources.  After removing 
duplicates, a total of 448 abstracts were screened and, 33 full-text articles reviewed. Four 
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papers presenting the results of psychometric reviews [8-10, 25] were identified and one 
paper describing recommendations by ICHOM [26] (Figure 1).  
 
Based on the recommendations made by these five papers, we identified six prostate 
cancer-specific PRO questionnaires for further review (EPIC-26, EPIC-50, UCLA-PCI, FACT-P, 
QLQ-PR25, and PC-QoL) and located the original development article for each [27-35].  
FACT-P [33] and EORTC QLQ-C30 [36] are generic cancer-related QoL instruments with an 
additional prostate cancer-specific module. The prostate cancer specific module of EORTC 
QLQ-C30 is known as QLQ-PR25 [34].  We evaluated only the prostate cancer specific 
subscales for these two PRO questionnaires.  An instrument, developed by Memorial Sloane 
Kettering Cancer Center (New York, US), known as STAR [3], to monitor PROs following 
radical prostatectomy in routine clinical practice is also included in this review because it is 
widely used, and was developed specifically for repeat use in men having radical 
prostatectomy.  Therefore, seven instruments are described in Table 2. 
 
Psychometric appraisal  
The detailed psychometric review of the seven identified instruments, based on their 
development papers is described below, and the results of their psychometric appraisal is 
shown in Table 3. Overall, the psychometric evidence supporting the instruments was 
patchy and variable in quality. 
 
Evidence supporting instrument acceptability was weak for all instruments except EPIC-50, 
with high floor and/or ceiling effects across most instruments. All instruments had evidence 
supporting their reliability, although this evidence was weak for STAR and FACT-P PCS.  
These scales (together with QLQ-PR25) only assessed one type of reliability (internal 
consistency). 
 
Conceptual Review 
Our conceptual review addressed the content validity of each instrument in terms of the 
extent to which the items in each instrument reflected the construct that the developers 
claimed the instrument measured.  The developers of six of the seven identified instruments 
themselves used the terms “HRQL” or “overall QL” to describe what  their instruments 
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measured (EPIC-26, EPIC-50, UCLA-PCI, EORTC QLQ-PR25, and PC-QoL).
1
  The remaining 
instrument, (STAR) claimed to measure “functional recovery” after radical prostatectomy.   
  
The results of our conceptual review are shown in Figures 2 to 8. For each instrument, we 
allocated each item (question) to one of Wilson & Cleary’s levels of outcome (i.e. “biological 
and physiological variables”, “symptom status”, “functional status”, “general health 
perceptions”, and “overall QoL”). This allowed us to critique the conceptual content of each 
instrument by determining which level of outcome each item represented. None of the 
seven instruments include items related to the Wilson and Cleary outcome level labelled as 
“biological and physiological variables”. All instruments include items related to “symptom 
status” or “functional status”, particularly sexual and urinary problems and all instruments 
except EPIC-26 include items about bowel problems. In addition, EPIC-50 and EORTC-QLQ 
also include hormonal symptoms and the FACT-P includes other symptoms and functional 
problems, such as weight loss, appetite and pain. 
 
STAR is the only instrument that includes an item related to “general health perceptions”, 
asking about the overall feeling related to the current state of health. 
 
All instruments included some items that can be labelled as “HRQoL”.  Across all 
instruments these are mostly focused on the subjective impact of physical health, with 
fewer items representing the perceived impact of mental health.  EPIC-26, EPIC-50 and PC-
QOL include the most items that can be labelled as HR“QoL”.  In general, most of these 
items reflect the subjective impact of physical aspects of health (e.g. the extent to which 
dripping or leaking urine is perceived as a problem or the extent to which changes in body 
weight are perceived as a problem).  PC-QOL also includes items that reflect the impact of 
mental aspects of health (e.g. concern/anxiety about treatment, recurrence, and quality of 
care).  However, items reflecting the subjective impact of social aspects of health were less 
common.  Only PC-QOL includes an item about worry arising from being unable to please a 
partner sexually, an aspect of social health.   
                                                        
1
 Please note that these are the terms are used by the developers.  They often did not explicitly define what 
these terms included and do not necessarily reflect the definitions used in the conceptual framework 
proposed by Wilson and Cleary.
14 
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In the items that could be labelled as Wilson & Cleary’s term “overall QOL” (though this was 
often described as HRQL by developers of the questionnaires) in the remaining instruments, 
there was a similar predominance of items asking about the subjective impact of physical 
aspects of health.  The HRQL items in QLQ-PR25 include three items about the subjective 
impact of physical health and one about the impact of mental health (feeling less 
masculine).  Similarly, the HRQL items in UCLA-PCI include four items about the subjective 
impact of aspects of physical health (e.g. the extent to which weight gain, weight loss and 
incontinence aids have been a problem) and one item about the impact of mental health 
(feeling less masculine as a result of treatment).  STAR and FACT-P PCS have the narrowest 
HRQL focus. STAR includes two HRQL items, both assessing the subjective impact of aspects 
of physical health (the extent to which urinary and bowel function are a problem).  FACT-P 
PCS includes three HRQL items, of which two assess the subjective impact of physical 
aspects of health (satisfaction with levels of pain and comfort level) and one assesses the 
impact of mental health (ability to feel like a man).   
 
Psychometric appraisal  
The detailed psychometric review of the seven identified instruments, based on their 
development papers is described below, and the results of their psychometric appraisal is 
shown in Table 3. Overall, the psychometric evidence supporting the instruments was 
patchy and variable in quality. 
 
Classical test theory 
Evidence supporting instrument acceptability was weak for all instruments except EPIC-50, 
with high floor and/or ceiling effects across most instruments. All instruments had evidence 
supporting their reliability, although this evidence was weak for STAR and FACT-P PCS.  
These scales (together with QLQ-PR25) only assessed one type of reliability (internal 
consistency). 
 
For all instruments there was evidence of at least one other form of validity.  This evidence 
was weakest for PCS (FACT-P) which only had weak evidence for known groups differences.  
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Validity evidence was moderately strong for the other instruments, across a range of 
different types of validity.    
 
Lastly, evidence regarding the responsiveness of all instruments was very limited which 
makes it impossible to assess the instruments’ ability to detect clinically important 
differences in HRQL in relation to treatment over time. 
 
Modern test theory 
No instrument was developed or subsequently analysed using item response theory or 
Rasch measurement theory. 
 
 
CONCLUSIONS 
 
We found that the developers of most of the seven identified prostate-cancer specific PROs 
claim that these instruments measure “HRQL” or “overall QoL”, but their items strongly 
focus on urinary, sexual and bowel symptoms and function. All questionnaires include some 
items with a more subjective element to determine the extent to which men are concerned 
or bothered by a particular symptom. However, no instrument includes the full range of 
items necessary to represent HRQL in terms of the subjective impact of physical, mental and 
social aspects of prostate cancer. These gaps do not only compromise the content validity of 
the six instruments that claim to measure HRQL but they also affect the interpretation of 
the scores and their suitability for use in research and service evaluation.  This means that in 
clinical practice the true impact of prostate cancer treatment is not reflected in the current 
outcomes. The currently available instruments do not measure the range of outcomes that 
are important to men. 
 
Generally, evidence of reliability and validity is incomplete for all instruments. EPIC-50, EPIC-
26 and UCLA-PCI and PC-QOL have most evidence for robust psychometric properties.  Of 
these, EPIC-26 has the advantage that it is well–used and has comparable psychometric 
properties to EPIC-50, but is considerably shorter. However, as none of the instruments has 
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evidence of responsiveness it is impossible to draw any conclusion about whether they are 
sensitive to clinically meaningful change.  None of the instruments has been evaluated using 
modern psychometric methods and consequently we have no evidence about how well they 
work at the individual patient level.   
 
Although only PC-QOL had content validity as a measure of HRQL (i.e. it included items 
reflecting the perceived impact of physical, mental and social aspects of health), closer 
inspection of the items across all of the instruments suggests that most reflect the 
recognised side effects of surgery. However, the relatively narrow focus and dearth of items 
reflecting patients’ subjective feelings about the impact of physical, mental and social 
aspects of health means that they may not reflect all the outcomes that are important to 
patients. There is a need for greater qualitative understanding of HRQL for men with 
prostate cancer and to develop questionnaire items that reflect this.  Additionally, further 
psychometric development work is needed, using modern psychometric methods (such as 
IRT or RMT) to determine the extent to which it is appropriate to use these questionnaires 
at the individual level.   
 
Our findings are limited by the fact that we used the instruments that were recommended 
by other reviews. The five reviews overlapped in their recommendations, especially for 
EPIC-50, EPIC-26 and UCLA-PCI.  As these recommendations are often the basis of how 
researchers and practitioners choose instruments, it is an appropriate shortlist for further 
critique. The authors of each review used slightly different psychometric criteria to reach 
their conclusions, but there was also much similarity in the criteria that were used. 
 
In addition, the review of questionnaire items and their conceptual content involves a 
degree of judgement.  We have made our definitions explicit and based them on the widely 
available and often cited literature in this area.  The categorisation of each item was 
undertaken by two of the authors and later also reviewed by the remaining authors.   
 
The results of our review, and especially the evaluation of conceptual content, suggest that 
the available PROs offer a limited evaluation of the outcomes after radical prostatectomy 
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that are relevant to men with prostate cancer. There are gaps in content and also 
inadequate evidence of reliability, validity and responsiveness of the existing instruments.  
 
In conclusion, several instruments provide the basis of measures of urinary symptoms 
and/or sexual function that could potentially be used at the group level. Although the focus 
on symptoms and functional outcomes is of interest to both clinicians and patients, there 
are other aspects of HRQL that need to be explored as important outcomes for men 
receiving surgery for prostate cancer.  As yet, there is no formal evidence to support the 
appropriateness of the questionnaires for use at the individual level.  
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Table 1. Psychometric definitions/tests and appraisal criteria, derived from Smith et al 2005 [22]. 
 
Psychometric property Definition/test Criteria for acceptability 
1. Item 
analysis/reduction 
Identification of items for possible elimination owing to weak 
psychometric performance; assessed on the basis of (1) unrotated 
principal component factor analysis to determine whether all items 
are measuring a single factor; and (2) item analyses for all items. 
Principal component factor analysis: All items should load on the first 
unrotated factor >0.30. 
 
Item analyses (applied to all items):  
Missing data <5%.  
No item redundancy (inter-item correlations ≤ 0.75). 
Item–total correlations >0.25 Maximum endorsement frequencies 
≤80% (i.e. the proportion of respondents who endorse each response 
category), including floor/ceiling effects <80% (i.e. response categories 
with high endorsement rates at the bottom/top ends of the scale, 
respectively).  
Aggregate adjacent endorsement frequencies ≥10%. 
2. Acceptability The quality of data; assessed by completeness of data and score 
distributions. 
Missing data for summary scores <5%. 
Even distribution of endorsement frequencies across response 
categories. 
Floor/ceiling effects for summary scores <10%. 
3. Reliability   
3.1 Internal 
consistency 
The extent to which items comprising a scale measure the same 
construct (e.g. homogeneity of the scale); assessed by Cronbach’s 
alpha and item–total correlations. 
Cronbach’s alphas for summary scores ≥0.70. 
Item–total correlations ≥0.20. 
Test–retest reliability correlations for summary scores ≥0.70. 
3.2 Test-retest 
reliability 
The stability of a measuring instrument; assessed by administering the 
instrument to respondents on two different occasions and examining 
the correlation between test and retest scores. 
Test–retest reliability correlations for summary scores ≥0.70. 
 
4. Validity   
4.1 Content validity The extent to which the content of a scale is representative of the 
conceptual domain it is intended to cover; assessed qualitatively 
during the questionnaire development stage through pre-testing with 
patients, expert opinion and literature review. 
Qualitative evidence from pre-testing with patients, expert opinion and 
literature review that items in the scale are representative of the 
construct being measured. 
 
4.2 Criterion-related 
validity 
  
4.2.1 Concurrent 
validity 
Evidence that the scale predicts a gold-standard criterion that is 
measured at the same time; assessed on the basis of correlations 
between the scale and the criterion measure. 
High correlation between the scale and the criterion measure. 
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4.2.2 Predictive 
validity 
Evidence that the scale predicts a gold-standard criterion that is 
measured in the future; assessed on the basis of correlations between 
the scale and the criterion measure. 
High correlation between the scale and the criterion measure. 
 
4.3 Construct validity   
4.3.1 Within-scale 
analyses 
Evidence that a single entity (construct) is being measured and that 
items can be combined to form a summary score; assessed on the 
basis of evidence of good internal consistency and correlations 
between scale scores (which purport to measure related aspects of 
the construct). 
Internal consistency (Cronbach’s alpha) ≥ 0.70. 
Moderate to high correlations between scale scores. 
 
4.3.2 Analyses against 
external criteria 
  
4.3.2.1 Convergent 
validity 
Evidence that the scale is correlated with other instruments measuring 
the same or similar constructs; assessed on the basis of correlations 
between the instrument and other similar instruments. 
Correlations are expected to vary according to the degree of similarity 
between the constructs that are being measured by each instrument. 
Specific hypotheses are formulated and predictions tested on the basis 
of correlations. 
4.3.2.2 Discriminant 
validity 
Evidence that the scale is not correlated with instruments measuring 
different constructs; assessed on the basis of correlations with 
instruments measuring different constructs. 
Low correlations between the instrument and instruments measuring 
different constructs. 
 
4.3.2.3 Known groups 
differences 
The ability of a scale to differentiate known groups; assessed by 
comparing scores for subgroups who are expected to differ on the 
construct being measured. 
Significant differences between known groups or difference of expected 
magnitude. 
 
4.3.2.4 Hypothesis 
testing 
The extent to which the scale confirms pre-defined hypotheses 
regarding expected associations or lack of association with external 
factors, such as patient characteristics. 
Significant moderate to high correlations, or significant associations in 
the expected direction. 
Expected lack of association confirmed. 
5. Responsiveness The ability of a scale to detect clinically important change over time; 
assessed by comparing scores before and after an intervention of 
known efficacy (on the basis of various methods including t-tests, 
effect sizes, standardised response means, or responsiveness 
statistics). 
Significant differences between known groups or difference of expected 
magnitude. 
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Table 2. Description of prostate cancer specific PROs  
 
PRO Authors 
 
Reviews 
recommending 
PROs  
Domains (no. items) Response 
options 
Scoring Target population Recall 
period 
Administration 
/ completion 
time 
STAR 
(Symptom 
Tracking and 
Reporting) 
Vickers et 
al 2010 [3] 
N/A 4 domains (15 items): Sexual 
function (6 items), urinary 
function (5 items), bowel 
function (2 items) and overall 
quality of life (1 item).  
3- to 6-
point Likert 
scales, and 
one 11-
point Likert 
scale. 
 
Item scores summed 
for the urinary and 
sexual function 
scales to give 
domain scores. 
Domain scores can 
also be transformed 
to a 0-100 scale. 
Men treated for 
early stage prostate 
cancer with radical 
prostatectomy. 
Last 4 
weeks. 
Self-
administered. 
Time to 
complete 
unknown. 
EPIC-26 
(Expanded 
Prostate 
Index 
Composite-
26)  
Szymanski 
et al 2010 
[27] 
Hedgepeth 
et al 2009 
[28] 
Schmidt et al 
2014 [9] 
Rnic et al 2013 
[10] 
Martin et al 
2015 [26] 
4 domains (26 items): Urinary 
domain with incontinence 
subscale (4), 
irritatation/obstruction 
subscale (4), overall urinary 
bother item (1); bowel domain 
(6)’ sexual domain (6); and 
vitality/hormonal domain (5). 
 
4- and 5- 
point Likert 
scales. 
Item scores summed 
for each scale and 
linearly transformed 
to 0-100 scale. 
Higher scores = 
better QoL. 
Men treated for 
early stage prostate 
cancer with 
brachytherapy / 
external beam 
radiation / radical 
prostatectomy ± 
adjuvant hormonal 
therapy. 
Last 4 
weeks. 
Self-
administered in 
10 minutes. 
EPIC-50  
(Expanded 
Prostate 
Index 
Composite) 
Wei et al 
2000 [29] 
Wei et al 
2002 [30] 
Schmidt et al 
2014 [9] 
Morris et al 
2009 [8] 
4 domains (50 items): urinary 
(12) - function (5) and bother 
(7); bowel (14) - function (7) 
and bother (7); sexual (13) - 
function (9) and bother (4); 
hormonal (11) - function (5) 
and bother (6). 
 
3- to 5-
point Likert 
scales. 
Item scores summed 
for each domain and 
linearly transformed 
to 0-100 scale. 
Higher scores = 
better QoL. 
Men treated for 
localised prostate 
cancer with 
brachytherapy / 
external beam 
radiation / radical 
prostatectomy ± 
adjuvant hormonal 
therapy. 
Last 4 
weeks. 
Self-
administered in 
15-20 minutes.  
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PRO Authors 
 
Reviews 
recommending 
PROs  
Domains (no. items) Response 
options 
Scoring Target population Recall 
period 
Administration 
/ completion 
time 
UCLA-PCI 
(University of 
California-Los 
Angeles 
Prostate 
Cancer Index)
 
 
Litwin et al 
1995 [31] 
Litwin et al 
1998 [32] 
Rnic et al 2013 
[10] 
Morris et al  
2009 [8] 
Hamoen et al 
2015 [25] 
6 domains (20 items): urinary 
function (5), sexual function 
(8), bowel function (4), urinary 
bother (1), sexual bother (1), 
bowel bother (1). 
3- to 5-
point Likert 
scales. 
Item scores summed 
for the function 
scales and all 
domain scores 
linearly transformed 
to 0-100 scales. 
Higher scores = 
better QoL. 
 
Men treated for 
localised early stage 
prostate cancer 
with surgery, 
radiotherapy or 
watchful waiting. 
Last 4 
weeks. 
Self-
administered in 
8-10 minutes.  
 
FACT-P 
(Functional 
Assessment 
of Cancer 
Therapy – 
Prostate)
 
 
Esper et al 
1997 [33] 
Morris et al 
2009 [8]
 
Hamoen et al 
2015 [25] 
6 domains (39 items). 
1 Prostate Cancer Subscale 
(PCS) titled ‘additional 
concerns’ (12 items).  
 
PCS 12 items: weight loss, 
appetite, pain bother, pain, 
pain activity limitation, 
comfort, masculine self-
perception, bowel movement, 
difficulty urinating, urinating 
frequency, urinating activity 
limitation, erection.  
 
5 generic FACT-G domains (27 
items): physical well-being (7), 
social/family well-being (7), 
emotional well-being (6), 
functional well-being (7). 
5-point 
Likert 
scales.  
Item scores are 
added to give 
summary score for 
each domain and a 
total FACT-P score. 
Physical and 
functional domain 
scores and the 
prostate-specific 
score produce the 
Treatment Outcome 
Index (TOI). Higher 
scores = b tter QoL. 
 
PSC score range=0-
48. 
Men with localised 
or metastatic 
prostate cancer. 
Past 7 
days. 
Self-
administered in 
8-10 minutes. 
QLQ-PR25 
(EORTC 
Prostate-
specific 
module)
  
van Andel 
et al 2008 
[34] 
Morris et al 
2009 [8] 
6 domains (25 items): urinary 
symptoms (8), incontinence 
aid (1), bowel symptoms (4), 
hormonal treatment related 
symptoms (6), sexual active 
4-point 
Likert 
scales.  
Item and scale 
scores transformed 
to a 0-100 scale. 
Higher scores = 
worsening 
Men with early or 
advanced localised 
prostate cancer. 
Past 
week 
and 
last 4 
weeks. 
Self-
administered in 
5-10 minutes. 
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PRO Authors 
 
Reviews 
recommending 
PROs  
Domains (no. items) Response 
options 
Scoring Target population Recall 
period 
Administration 
/ completion 
time 
 
 
(2), sexual functioning (4). 
 
symptoms or better 
functioning. 
PC-QoL 
(Prostate 
Cancer – 
Quality of 
Life)  
Giesler et 
al 2000 
[35] 
Schmidt et al 
2014 [9] 
Rnic et al 2013 
[10] 
 
10 domains (52 items): Urinary 
function (5), role activity 
limitations (5), and bother (4); 
sexual function (7), role 
activity limitations (5), and 
bother (6); bowel function (7), 
role activity limitations (5) and 
bother (4); cancer worry (4). 
3- to 7-
point Likert 
scales. 
Item scores summed 
and linearly 
transformed to 0-
100 score range for 
each domain. Higher 
scores = better QoL. 
Men with clinically 
localised prostate 
cancer treated with 
radical 
prostatectomy, 
radiation or 
watchful waiting. 
Past 4 
weeks. 
Self-
administered in 
15 minutes. 
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Table 3. Appraisal of psychometric evidence for prostate cancer-specific PROs. 
 
 STAR [3] EPIC-26 [27,28] EPIC-50 [29,30]  UCLA-PCI [31,32] PCS (FACT-P) [33] EORTC QLQ-PR25 [34]  PC-QoL [35] 
1. Item analysis/reduction + ++ 0 ++ 0 0 ++ 
2. Acceptability + + ++ + + + + 
3. Reliability        
3.1 Internal consistency + +++ ++ ++ + ++ + 
3.2 Test-retest reliability 0 ++ ++ ++ 0 0 ++ 
4. Validity        
4.1 Content validity ++ + ++ ++ + ++ +++ 
4.2 Criterion-related validity        
4.2.1 Concurrent validity 0 + 0 0 0 0 0 
4.2.2 Predictive validity + 0 0 0 0 0 0 
4.3 Construct validity        
4.3.1 Within-scale analyses ++ ++ ++ ++ 0 ++ ++ 
4.3.2 Analyses against external criteria        
4.3.2.1 Convergent validity 0 ++ ++ ++ 0 0 ++ 
4.3.2.2 Discriminant validity 0 ++ 0 + 0 + 0 
4.3.2.3 Known groups differences ++ 0 +++ ++ + +++ ++ 
4.3.2.4 Hypothesis testing ++ 0 0 + 0 0 0 
5. Responsiveness 0 0 0 0 + + 0 
6. Modern test theory 0 0 0 0 0 0 0 
0: not reported or no evidence in favour; +: limited evidence in favour; ++: some acceptable evidence in favour, but some aspects fail criteria or not 
reported; +++: acceptable evidence in favour. 
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Figure 1. PRISMA flowchart  
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Figure 2. STAR item and domain mapping based on the Wilson and Cleary HRQL conceptual model  
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Figure 3. EPIC-26 item and domain mapping based on the Wilson and Cleary HRQL conceptual model  
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Figure 4. EPIC-50 item and domain mapping based on the Wilson and Cleary HRQL conceptual model  
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Figure 5. UCLA-PCI item and domain mapping based on the Wilson and Cleary HRQL conceptual model  
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Figure 6. FACT-P Prostate Cancer Subscale (PCS) item mapping for the Prostate Cancer Subscale based on 
the Wilson and Cleary HRQL conceptual model  
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Figure 7. EORTC QLQ-PR25 item and domain mapping based on the Wilson and Cleary HRQL conceptual 
model  
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Figure 8. PC-QoL item and domain mapping based on the Wilson and Cleary HRQL conceptual model  
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